Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track GILD with free AI briefings, catalyst countdowns, and dilution alerts.

GILD — GILEAD SCIENCES, INC.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$5.4B Cash on Hand

CF+ Cash Runway

2.1% Short Interest

💊 Upcoming FDA Decisions

PDUFA Date	Drug	Indication	Type	PoA
2026-12-23	—	Multiple Myeloma &ndash	BLA	83%

PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →

🧪 Upcoming Trial Catalysts

2026-07-01 · Phase 1 — Active Trial — A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age an
2026-07-01 · Phase 1 — Recruiting — Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Par
2026-08-01 · Phase 4 — Active Trial — Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
2026-09-01 · Phase 3 — Active Trial — Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
2026-09-01 · Phase 2 — Active Trial — Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepati
2026-09-30 · NA — Active Trial — Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and

📊 Drug Pipeline

Drug	Indication	Phase	Status
Biktarvy Pill	Hiv	NA	WITHDRAWN
TL+D antiretroviral	HIV	NA	COMPLETED
3rd ARV Agent	HIV-1-infection	PHASE4	RECRUITING
ATV	HIV-1-infection	PHASE4	RECRUITING
B/F/TAF	HIV-1-infection	PHASE4	COMPLETED
B/F/TAF (High Dose TOS)	HIV-1-infection	PHASE4	RECRUITING
B/F/TAF (High Dose)	HIV-1-infection	PHASE4	RECRUITING
B/F/TAF (Low Dose TOS)	HIV-1-infection	PHASE4	RECRUITING
B/F/TAF (Low Dose)	HIV-1-infection	PHASE4	RECRUITING
B/F/TAF (Lowest Dose TOS)	HIV-1-infection	PHASE4	RECRUITING

💰 Cash Runway & Dilution Risk

GILD holds $5.4B in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for GILD free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-06-16	Dickinson Andrew D	Sale	$21.5M
2026-06-16	Mercier Johanna	Sale	$15.5M
2026-06-16	Mercier Johanna	Sale	$15.5M
2026-06-16	Mercier Johanna	Sale	$15.6M
2026-06-11	Dickinson Andrew D	Purchase	$0

Get the full GILD picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for GILD and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z